• Technology and Data
  • Front End Sales and Marketing
  • Allergy
  • HIV
  • Women's Health
  • Migraine
  • Compounding
  • Continuous Glucose Monitoring
  • Mental Health Awareness
  • Veterinary Pharmacy
  • CBD
  • Infectious Disease
  • Eye Health
  • Digestive Health
  • Biosimilars
  • Influenza
  • Shingles
  • COPD Management
  • Pediatrics
  • Generics
  • Pain Management
  • COVID-19
  • Immunization
  • Oncology
  • Anticoagulants
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Respiratory
  • Heart Health
  • Cardiovascular Clinical Consult

Evaluating Analgesic Use During COVID-19


Mean days of therapy per 1000 patient-days were reduced across medication categories.

During the COVID-19 pandemic, costs associated with the use of opioid analgesics were significantly reduced, according to a poster presented at the 2021 ASHP Midyear Clinical Meeting & Exhibition, held virtually December 5 through 9.1

In the current single-center, retrospective study, researchers sought to evaluate the use of both opioid and nonopioid analgesics during the COVID-19 pandemic. Data from both before and after the COVID-19 pandemic were compared, measured using days of therapy per 1000 patient-days and drug cost per 1000 patient-days.

Nonopioid drug classes included anxiolytics, induction agents, nonsteroidal anti-inflammatory drugs, regional/local anesthetics, sedatives, sedative/hypnotics, skeletal muscle relaxants, and other analgesics.

Following the start of the pandemic, the study center experienced a “significant reduction” in mean opioid and nonopioid days of therapy per 1000 patient days (1024.1±79.6 vs 898.8±121.4 and 1415.6±40 vs 1357.3±84.6). A significant reduction in mean drug cost per 1000 patient-days for opioids was also noted ($2.98±$0.57 vs $2.15±$0.31); the same reduction was not seen with nonopioid medications.

“Many variables may have contributed to the significant decrease in opioid use during the COVID-19 pandemic,” the authors noted; these variables include ongoing provider education, efforts to withhold the use of ventilators in patients with COVID-19, and a decrease in elective surgeries.


  1. Lowe H, Nicholson J, Guzman O, Egan B, Wright K. Opioid and non-opioid analgesic utilization during the COVID-19 pandemic. Presented at: ASHP 2021 Midyear Clinical Meeting & Exhibition; December 5-9, 2021.
Related Videos
© 2023 MJH Life Sciences

All rights reserved.